# An assay suite featuring hiPSC-derived neurons and support cells, to test toxicants and industrial chemicals for developmental neurotoxic effects

> **NIH NIH R44** · VALA SCIENCES, INC. · 2024 · $1,217,093

## Abstract

This “direct to Phase II” project, proposed in response to RFA-ES-23-008 “Novel Approaches for Developmental
Neurotoxicity Testing (R43/R44)”, will develop a suite of in vitro assays to test compounds for potential
developmental neurotoxic (DNT) effects. Neurodevelopmental disorders (NDs, including autism spectrum
disorder, intellectual disabilities, attention-deficit/hyperactivity and others) affect at least 15% of people in the
USA, appear in childhood/early adulthood, and cannot be cured. NDs originate from dysregulation of brain
development during early life (fetal, neonatal, and childhood), during which the developing CNS is particularly
vulnerable to environmental toxicants and many of these chemicals have been linked to NDs (e.g., mercury,
pesticides, air pollutants). In the past, such compounds have been investigated for ND effects, via
epidemiological studies, only after they cause neurotoxicity to adults; this approach has tragic, global,
consequences, since decades of research are required to establish the links between adult neurotoxicity and
DNT, during which thousands of children become impaired through exposure to the culprit toxicant. Our project
will develop standardized, high throughput, assays to test chemicals for such effects. The DevNeuroToxAssay
(DNTA) suite will include assays to test compounds for effects on neurogenesis, a key processes in early brain
formation (DNTA-Neurogenesis), on neuronal circuit formation/activity, relevant to neuronal circuits within the
brain (DNTA-Neurocircuitry), on development of 3-D neural organoids, (DNTA-Neural Organoids), and on
development and function of the blood-brain barrier, a structure that protects the brain from toxicants and
pathogens (DNTA-BBB). The DNTA assays will feature neurons, glial, and support cells derived from human
induced pluripotent stem cells, cultured in either 2-D or 3-D configurations. Automated digital microscopy will be
used to quantify effects of chemicals on biomarkers and structures (high content analysis, HCA); additionally,
effects of compounds on biological neuronal circuits will be quantified via collection/analysis of digital movies
(frame rates up to 100 frames per second, using Kinetic Image Cytometry, [KIC]). Compounds from the National
Toxicology Program DNT chemical library will be used to develop, validate, and demonstrate the utility of the
DNTAs. Since the DNTAs will feature human cells, the results obtained will be more predictive of human
outcomes vs. tests conducted on animals or animal cells. Vala Sciences Inc. has recently developed similar
assays to test candidate anti-HIV therapeutics for neurotoxicity, and this previous experience will expedite rapid
development of the DNTAs.

## Key facts

- **NIH application ID:** 10884846
- **Project number:** 1R44ES036385-01
- **Recipient organization:** VALA SCIENCES, INC.
- **Principal Investigator:** Kara L Gordon
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,217,093
- **Award type:** 1
- **Project period:** 2024-06-19 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10884846

## Citation

> US National Institutes of Health, RePORTER application 10884846, An assay suite featuring hiPSC-derived neurons and support cells, to test toxicants and industrial chemicals for developmental neurotoxic effects (1R44ES036385-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10884846. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*